Related Experiment Videos
[McAb LC-1 against human lung cancer]
Shi Yan Sheng Wu Xue Bao
|September 1, 1989
Summary
Researchers developed LC-1, a new monoclonal antibody targeting common antigens in human lung cancers. This antibody shows promise for diagnosing and potentially treating non-small cell lung cancer and small cell lung carcinoma.
Area of Science:
- Immunology
- Oncology
- Biochemistry
Context:
- Tumor-associated antigens in human lung cancer have been recognized, but common antigens or epitopes are less understood.
- Previous research identified monoclonal antibodies (McAbs) like LAC-122, LAC-210, and LAC-163 against human non-small cell lung cancer (NSCLC) and LSC McAbs against small cell lung carcinoma (SCLC).
- An immunotoxin using McAb LAC-122 conjugated with Ricin A chain demonstrated in vitro cytotoxicity against the lung adenocarcinoma cell line SPC-A-1.
Purpose:
- To identify and characterize novel monoclonal antibodies targeting common antigens in human lung cancer.
- To evaluate the reactivity of a newly developed monoclonal antibody, LC-1, against various lung cancer types and normal tissues.
Summary:
- A hybridoma fusion yielded 20 hybridoma cell lines whose supernatants reacted with target lung cancer cells.
- One monoclonal antibody, designated LC-1 (IgM isotype), was selected after further cloning.
- LC-1 demonstrated positive reactivity in ABC staining across 12 non-small cell lung cancers (including adenocarcinoma, squamous carcinoma, and giant cell carcinoma, with one exception) and all 6 small cell lung cancers tested. It also reacted with 11 other tumor types.
Impact:
- LC-1 shows potential as a diagnostic marker for various types of human lung cancer, including both NSCLC and SCLC.
- The antibody's reactivity with common lung cancer antigens suggests broader applicability in immunotherapeutic strategies.
- Further research into LC-1 could lead to improved diagnostic tools and targeted therapies for lung cancer patients.